Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

NETWORK 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2

Conditions

Neuroblastoma 2Melanoma 2

Interventions

Cyclophosphamide 21Isotretinoin 14Etoposide 13Topotecan 12Irinotecan 12dinutuximab 10Temozolomide 10Magnetic Resonance Spectroscopy 10Doxorubicin 10Melphalan 9sargramostim 8Vincristine 8Filgrastim 7Cisplatin 7Specimen Handling 6Granulocyte-Macrophage Colony-Stimulating Factor 6Granulocyte Colony-Stimulating Factor 6Carboplatin 63-Iodobenzylguanidine 6X-Rays 5Phantoms, Imaging 5Busulfan 5Biopsy 5fludarabine 4etoposide phosphate 4aldesleukin 4Thiotepa 4Stem Cell Transplantation 4Radiotherapy 4Nuclear Medicine Department, Hospital 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Neuroblastoma × lorukafusp alfa × Clear all
NCT01334515 2019-10-21

Biological Therapy, Sargramostim, and Isotretinoin in Treating Patients With Relapsed or Refractory Neuroblastoma

Children's Oncology Group

Phase 2 Completed
52 enrolled 11 charts
CNS

Neuroblastoma

NCT00082758 2015-02-12

hu14.18-Interleukin-2 Fusion Protein in Treating Young Patients With Recurrent or Refractory Neuroblastoma

Children's Oncology Group

Phase 2 Completed
39 enrolled 8 charts
CNS

Neuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡